Company: IMRX
Filing Date: 2025-05-05
Form Type: 10-Q
Source: 0001790340-25-000061
Chunk: 323

Company: Immuneering Corp
Filing Date: 2025-05-05
Form: 10-Q
Item: Part I, Item 1
Chunk 323
---
 Issuance of common stock through employee stock purchase plan98,45098 —— 133,794 — — 133,892 Stock-based compensation expense—— —— 1,692,267 — — 1,692,267 Net loss—— —— — — (15,046,132)(15,046,132)Balance at March 31, 202535,985,702$35,985 —$— $281,148,253 $— $(239,341,318)$41,842,920 

Class A Common StockClass B Common StockAdditionalPaid-In CapitalAccumulated OtherComprehensive LossAccumulatedDeficitTotalStockholders' EquitySharesPar ValueSharesPar ValueBalance at December 31, 202329,271,629$29,272 —$— $253,806,267 $(778)$(163,258,578)$90,576,183 Issuance of common stock upon exercise of stock options229,299229 —— 732,229 — — 732,458 Issuance of common stock through employee stock purchase plan152,427152 —— 247,313 — — 247,465 Stock-based compensation expense—— —— 1,474,758 — — 1,474,758 Net loss—— —— — — (14,307,829)(14,307,829)Other comprehensive income—— —— — (306)— (306)Balance at March 31, 202429,653,355$29,653 —$— $256,260,567 $(1,084)$(177,566,407)$78,722,729 

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

9

IMMUNEERING CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE THREE MONTHS ENDED MARCH 31, 2025 and 2024

(Unaudited)

Three Months Ended March 31,20252024Cash flows from operating activities:Net loss$(15,046,132)$(14,307,829)Adjustment to reconcile to net loss to net cash used in operating activities:  Depreciation and amortization expense85,261 90,209 Reduction in carrying amount of right-of-use assets83